重组人生长激素治疗慢性阻塞性肺疾病营养不良安全性研究进展

Safety of recombinant human growth hormone in chronic obstructive pulmonary disease with malnutrition

慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）患者大多并发营养不良，其原因众多；而营养不良是判断COPD患者预后一项独立的影响因素，因此改善COPD患者的营养状况尤其重要。重组人生长激素（recombinant human growth hormone，rhGH）能促进蛋白质的合成、脂肪及糖合理利用、增加呼吸肌收缩力、改善COPD患者的营养状态，但临床应用中也存在一些不良反应，故对rhGH治疗COPD营养不良的安全性进行研究，可为改善COPD患者的营养状况提供理论依据。

Patients with chronic obstructive pulmonary disease （COPD） mostly suffer malnutrition, and the reasons are numerous. Malnutrition is a independent factor for the prognosis. Recombinant human growth hormone（rhGH） is able to promote protein synthesis,utilize fat and glucose reasonably,increase the myotility of respiratory muscle, but it also has many adverse effects in clinical application. Therefore,to study safety of rhGH in COPD will provide evidence for treating COPD sufferers with malnutrition.